Alpine Immune Sciences, Inc. Share Price

Equities

ALPN

US02083G1004

Biotechnology & Medical Research

Delayed Nasdaq 21:00:00 17/05/2024 BST 5-day change 1st Jan Change
64.97 USD +0.02% Intraday chart for Alpine Immune Sciences, Inc. -.--% +240.87%
Sales 2022 30.06M 2.36B Sales 2023 58.88M 4.63B Capitalization 1.11B 86.95B
Net income 2022 -57M -4.48B Net income 2023 -32M -2.52B EV / Sales 2022 3.79 x
Net cash position 2022 223M 17.57B Net cash position 2023 317M 24.97B EV / Sales 2023 13.4 x
P/E ratio 2022
-4.25 x
P/E ratio 2023
-29.6 x
Employees 142
Yield 2022 *
-
Yield 2023
-
Free-Float 96.04%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Alpine Immune Sciences, Inc.

1 day+0.02%
3 months+62.63%
6 months+225.83%
Current year+240.87%
More quotes
Current year
17.32
Extreme 17.32
65.00
1 year
8.33
Extreme 8.33
65.00
3 years
4.82
Extreme 4.82
65.00
5 years
2.05
Extreme 2.05
65.00
10 years
2.05
Extreme 2.05
65.00
More quotes
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Related indices
More about the company